About Kleem Chaudhary
Kleem Chaudhary is a president & CEO, director at Hyku Biosciences.
Kleem Chaudhary reports to the SEC as an officer of 1 public company: Checkmate Pharmaceuticals (CMPI).
Kleem Chaudhary first appears on SEC filings in 2020.
Experience
This experience comes from Kleem Chaudhary's profile and from SEC filings. For roles taken from filings, the years are when the filings name Kleem Chaudhary in the role, so the role may have started earlier or lasted longer.
RC
Raven Healthcare Incubator (RA Capital) Current
Venture Partner
2026 – Present
Hyku Biosciences Inc. Current
President & Chief Executive Officer (2024 – Present)
Director
2024 – Present · Concord, MA
Develops small-molecule medicines for people with cancer.
RT
Redona Therapeutics
Chief Operating and Business Officer
2022 – 2024
CI
Checkmate Pharmaceuticals, Inc.
Chief Business Officer
2019 – 2022 · Public company (CMPI)
BI
Biogen
Head Business Development & Licensing
2018 – 2019
PI
Portal Instruments
Board Observer
2017 – 2018
TP
Takeda Pharmaceuticals
Senior Director, Business Development & Licensing
2016 – 2018
NO
Novartis
Director/Associate Director, Business Development & Licensing
2007 – 2016
GI
Gilead Sciences Inc.
Research Scientist
2003 – 2006
Key Colleagues at Startups
The people Kleem Chaudhary works with at each company, as listed on that company's latest Form D.
Hyku Biosciences Inc. · Form D, Aug 13, 2026
JG
John Gustofson
President and director
MW
Matthias Van Woensel
Partner and director
JN
Janwillem Naesens
Managing Partner Oncology &, director